LAKE ZURICH — Fresenius Kabi stated it has been granted an expanded use of a dietary drug, which the Meals and Drug Administration says can now be prescribed for infants.
“The FDA approval of SMOFlipid for pediatric sufferers represents an essential growth of our parenteral diet portfolio and our continued dedication to offering modern diet merchandise to our medical companions and the sufferers they serve,” stated Gordon Sacks, senior director Medical Affairs, Fresenius Kabi USA.
Parenteral diet is the intravenous administration of amino acids (protein), carbohydrates (dextrose), lipids (fat), electrolytes, nutritional vitamins and different hint components for sufferers who can not digest or soak up adequate diet through the gastrointestinal tract. It may be offered within the hospital, in long-term care amenities, or at house.
Comments
0 comments